528523-46-8

Upstream product

• 58479-61-1 tert-butylchlorodiphenylsilane 
• 1009093-14-4 ((1R,2R)-2-hydroxy-1-hydroxymethyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 46032-98-8 (1R,2R)-2-amino-1-phenylpropane-1,3-diol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1009092-95-8 C₄₅H₆₂FN₅O₇ 
• 1009094-04-5 C₄₅H₆₂N₈O₆ 
• 1009094-03-4 C₄₅H₆₄N₆O₆ 
• 1009092-90-3 C₄₅H₆₃N₅O₇ 
• 1009092-92-5 C₂₄H₃₁NO₆S 
• 1009092-93-6 C₁₉H₃₀N₂O₃ 
• 1009092-91-4 tert-butyl (4R,5R)-4-(hydroxymethyl)-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate 
• 1009092-94-7 C₁₁H₁₈N₂O 
• 1009093-77-9 C₃₃H₄₃NO₄Si 
• 528523-55-9 diethyl (2S,3R,4S)-1,1-difluoro-2,4-dihydroxy-3-(palmitoylamino)-4-phenylbutylphosphonate 
• 528523-57-1 diethyl (3R,4S)-1,1-difluoro-4-hydroxy-3-([pentadecylcarbonyl]amino)-4-phenylbutylphosphonate 
• 528523-47-9 tert-butyl (1R,2S)-1-({[tert-butyl(diphenyl)silyl]oxy}methyl)-2-hydroxy-2-phenylethylcarbamate 
• 528523-51-5 (4R,5S)-4-[(S)-2-(Diethoxy-phosphoryl)-2,2-difluoro-1-hydroxy-ethyl]-2,2-dimethyl-5-phenyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 528523-53-7 tert-butyl (4R,5S)-4-[2-(diethoxyphosphoryl)-2,2-difluoroethyl]-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate 

Relevant academic research and scientific papers

Synthesis of non-competitive inhibitors of sphingomyelinases with significant activity

A series of short-chain analogues of N-palmitoylsphingosine-1-phosphate, modified by replacement of the phosphate and the long alkenyl side chain with hydrolytically stable difluoromethylene phosphonate and phenyl, respectively, were prepared to study the structure-activity relationship for inhibition of sphingomyelinase. The study revealed that inhibition is highly dependent upon the stereochemistry of the asymmetric centers of the acylamino moiety, and resulted in identification of a non-competitive inhibitor with the same level of inhibitory activity of schyphostatin, the most potent of the few known small molecular inhibitors of sphingomyelinase.

Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.